The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果